Table 2.
Treatment details and patient disposition (safety analysis set)
| Patient disposition | Safety analysis set (N = 248) |
|---|---|
| Median (range) follow-up, months | 6.1 (0.1─13.1) |
| Dose reduction or interruption, n (%) | 87 (35.1) |
| AEa | 78 (31.5) |
| Othera | 19 (7.7) |
| Unknown | 1 (0.4) |
| Discontinuation, n (%) | 150 (60.5) |
| Insufficient effectb | 56 (22.6) |
| AE except for deathb | 39 (15.7) |
| Deathb | 28 (11.3) |
| Other | 27 (10.9) |
AE adverse event, n number of patient
aAllowing for overlapped patients
bIncluding patients with progressive disease who were analyzed in the effectiveness analysis set